Cabozantinib: Interim Phase II data

Updated interim data from 51 evaluable patients in the cohort of subjects with advanced epithelial ovarian cancer in the lead-in stage of an ongoing, adaptive, international Phase II trial showed that once-daily oral cabozantinib produced an ORR of 24% at week 12, with 5 additional partial responses awaiting confirmation. The 12-week disease control rate (DCR) was 58%. At a median follow-up of 4 months, median PFS and duration of response have not been reached. Enrollment in the cohort was stopped at 68 patients due to an observed high rate of clinical activity.

Additionally, updated interim data from 100 evaluable patients in the cohort of subjects with metastatic castration-resistant prostate cancer (CRPC) in the lead-in stage of the trial showed that cabozantinib produced an ORR of 5% at week 12, with 3 additional partial responses awaiting confirmation. The 12-week DCR was 71%. At a median follow-up of 4 months, median PFS has not been reached. Enrollment in the cohort was stopped at 168 patients due to an observed high rate of clinical activity. ...